NLA Recommendations & Statements
The National Lipid Association (NLA) recently convened an Expert Panel on Statin Safety to examine various aspects of statin therapy and to determine its safety, patient tolerance and effectiveness.
The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)).
Click here to view the manuscript.
Adapted from an article in the Journal of Clinical Lipidology (JCL) titled, The Importance of Non-HDL Cholesterol Reporting in Lipid Management1
In connection with the Familial Hypercholesterolemia ("FH") initiative of the Foundation of the National Lipid Association, the NLA held a consensus conference in January 2011 to bring together experts on FH for the generation of an NLA statement of clinical guidance regarding the diagnosis and treatment FH. Click here to view the manuscript, published in the May 2011 edition of the Journal of Clinical Lipidology.